Systematic review: Cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 3, 2015, Pages 243-257

  Chang, M L ^a   Liaw, Y F ^a   Hadziyannis, S J ^b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; TELBIVUDINE; VIRUS RNA; ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELL KILLING; CHRONIC HEPATITIS B; CONSOLIDATION CHEMOTHERAPY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE EXACERBATION; DISEASE SEVERITY; FOLLOW UP; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SEROCONVERSION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; VIRAL CLEARANCE; ADULT; BLOOD; HEPATITIS B, CHRONIC; LIVER CIRRHOSIS; RECURRENT DISEASE; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 84936845603     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13272     Document Type: Review

References (47)

1. Ott JJ, Stevens GA, Groeger J, Wiersma ST,. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30: 2212-9.
2. Liaw YF, Chu CM,. Hepatitis B virus infection. Lancet 2009; 373: 582-92.
3. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
4. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.
5. Liaw YF, Leung N, Kao JH, et al,. Asian-Pacific Consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-83.
6. Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ,. Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007; 12: 73-82.
7. Zoutendijk R, Hansen BE, van Vuuren AJ, Boucher CA, Janssen HL,. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis 2011; 204: 415-8.
8. Chevaliez S, Hézode C, Bahrami S, Grare M, Pawlotsky JM,. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol 2013; 58: 676-83.
9. Chotiyaputta W, Peterson C, Ditah FA, Goodwin D, Lok AS,. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol 2011; 54: 12-8.
10. Han SH, Jing W, Mena E, et al,. Adherence, persistence, healthcare utilization, and cost benefits of guideline-recommended hepatitis B pharmacotherapy. J Med Econ 2012; 15: 1159-66.
11. Fung SK, Wong F, Hussain M, Lok AS,. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2004; 11: 432-8.
12. Chien RN, Liaw YF,. Short-term lamivudine therapy in HBeAg-negative chronic active hepatitis B in Taiwan. Antivir Ther 2006; 11: 947-52.
13. Chan HL, Wang H, Niu J, Chim AM, Sung JJ,. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther 2007; 12: 345-53.
14. Huang YH, Wu JC, Chang TT, et al,. Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan. J Viral Hepat 2003; 10: 277-84.
15. Marcellin P, Lau GK, Bonino F, et al,. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
16. Lai CL, Shouval D, Lok AS, et al,. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006 Mar; 9: 1011-20.
17. Bonino F, Marcellin P, Lau GK, et al,. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56: 699-705.
18. Shouval D, Lai CL, Chang TT, et al,. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009; 50: 289-95.
19. Marcellin P, Bonino F, Lau GK, et al,. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009; 136: 2169-79. e1-4.
20. Paik YH, Kim JK, Kim do Y, et al,. Clinical efficacy of a 24-months course of lamivudine therapy in patients with HBeAg negative chronic hepatitis B: a long-term prospective study. J Korean Med Sci 2010; 25: 882-7.
21. Liang Y, Jiang J, Su M, et al,. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Aliment Pharmacol Ther 2011; 34: 344-52.
22. Chan HL, Wong GL, Chim AM, Chan HY, Chu SH, Wong VW,. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients. Antivir Ther 2011; 16: 1249-57.
23. Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E,. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 2012; 143: 629-36. e1.
24. Jin YJ, Kim KM, Yoo DJ, et al,. Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patients. Virol J 2012; 9: 239.
25. Jeng WJ, Sheen IS, Chen YC, et al,. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology 2013; 58: 1888-96.
26. He D, Guo S, Chen W, et al,. Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative. BMC Infect Dis 2013; 13: 458.
27. Kim YJ, Kim K, Hwang SH, et al,. Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients. Clin Mol Hepatol 2013; 19: 300-4.
28. Chen CH, Lu SN, Hung CH, et al,. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. J Hepatol 2014; 61: 515-22.
29. Seto WK, Hui AJ, Wong VW, et al,. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. Gut 2015; 64: 667-72.
30. Patwardhan VR, Sengupta N, Bonder A, Lau D, Afdhal NH,. Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides. Aliment Pharmacol Ther 2014; 40: 804-10.
31. Sohn HR, Min BY, Song JC, et al,. Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs. BMC Infect Dis 2014; 14: 439.
32. Jiang JN, Huang ZL, He LX, et al,. Residual amount of HBV DNA in serum is related to relapse in chronic hepatitis B patients after cessation of nucleos(t)ide analogs. J Clin Gastroenterol 2015; 49: 323-8.
33. Liu F, Wang L, Li XY, et al,. Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients. J Gastroenterol Hepatol 2011; 26: 456-60.
34. Ha M, Zhang G, Diao S, et al,. A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir. Arch Virol 2012; 157: 285-90.
35. Chi H, Hansen BE, Yim C, et al,. Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B. Aliment Pharmacol Ther 2015; 41: 867-76.
36. Liaw YF, Kao JH, Piratvisuth T, et al,. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6: 531-61.
37. Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M,. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009; 51: 581-92.
38. Hadziyannis SJ, Vassilopoulos D, Sevastianos V, Hadziyannis E,. Can nucleos(t)ide analogue (NA) therapy ever be stopped in HBeAg-negative chronic hepatitis B? Curr Hepatitis Rep 2014; 13: 256-63.
39. Hadziyannis S, Liaw YF,. Discontinuation of long-term NA therapy in HBeAg-negative chronic hepatitis B. Gut 2015; 64: 1005-6.
40. Jeng WJ, Sheen IS, Liaw YF,. Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B. Clin Gastroenterol Hepatol 2010; 8: 541-5.
41. Lampertico P,. Oral antiviral therapy for HBeAg negative chronic hepatitis B: better stop or continue? Gut 2015; 64: 526-8.
42. Chang ML, Jeng WJ, Liaw YF,. Clinical events after cessation of lamivudine therapy in patients recovered from hepatitis B flare with hepatic decompensation. Clin Gastroenterol Hepatol 2015; 13: 979-86.
43. Chen YC, Jeng WJ, Chien RN, Liaw YF,. Hepatocellular carcinoma development in HBe-negative hepatitis B cirrhotic patients with entecavir treatment. J Hepatol 2013; 58: S214.
44. Hadziyannis SJ,. Letter: safe and effective cessation of long-term nucleos(t)ide analogue therapy in noncirrhotic patients with HBeAg-negative chronic hepatitis B. Aliment Pharmacol Ther 2015; 41: 236-7.
45. Chen YC, Jeng WJ, Chu CM, Liaw YF,. Decreasing levels of HBsAg predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection. Clin Gastroenterol Hepatol 2012; 10: 297-302.
46. Seto WK, Wong DK, Fung J, et al,. Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. Hepatol Int 2012; 7: 119-26.
47. Tseng TC, Liu CJ, Su TH, et al,. Young chronic hepatitis B patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation. J Infect Dis 2012; 206: 1521-31.